CA-ANDERSEN-GLOBAL
10.6.2022 12:17:06 CEST | Business Wire | Pressemeddelelse
Andersen Global fortsætter sin ekspansion på det nordiske marked gennem samarbejdsaftaler med det danske advokatfirma Bachmann/Partners og det finske advokatfirma I&O Partners. Med udgangspunkt i de eksisterende samarbejdende virksomheder Hellström Law og Unum i Sverige og Braekhus i Norge, styrker disse tilføjelser organisationens omfattende og integrerede skattemæssige og juridiske dækning i regionen.
Med kontorer i København og Aarhus tilbyder Bachmann/Partners en bred vifte af tjenester, herunder skattestrid og rådgivning, moms, punktafgifter, strafferetlig skatteret, arve- og ejendomsplanlægning for private og familieejede virksomheder med stor formue, international skatte- og erhvervsret. Bachmann/Partners, som er anerkendt af The Legal 500 som en konkurrencedygtig virksomhed i regionen, blev grundlagt i 2016 af ledende partner Christian Bachmann og leverer tjenester til lokale og internationale kunder.
”Vi har gennem årene opbygget vores omdømme på baggrund af vores store kendskab til dansk erhvervsliv, især vores specialisering i alle skatteretlige forhold”, siger Christian. ”Vi ser frem til at arbejde sammen med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fastholder en konkurrencefordel på markedet og leverer omfattende løsninger til kunder globalt”.
I&O Partners blev grundlagt i 2015 og bistår kunder inden for områder som bank og finans, virksomhedsrådgivning, erhverv, tvistbilæggelse, ansættelse, fusioner og opkøb, IP-teknologi, omstrukturering og privat formue. Under ledelse af ledende partner Andrei Aganimov arbejder virksomhedens team på mere end 16 fagfolk tæt sammen med nationale og internationale virksomheder såvel som private kunder.
”Virksomheden er vokset ret hurtigt siden vores grundlæggelse for næsten syv år siden, og vores samarbejde med Andersen Global er næste skridt i vores vækst og udvikling”, siger Andrei. ”Vores samarbejde positionerer os til at udnytte den kollektive styrke i en global organisation, overgå kundernes forventninger og levere problemfri service”.
”Bachmann/Partners og I&O Partners deler et stærkt engagement i klassens bedste service og en passion for forvaltning og gennemsigtighed”, siger Andersen Globals bestyrelsesformand og CEO Mark Vorsatz. ”Deres teams vil være et stort aktiv til at imødekomme vores kunders voksende behov og vil arbejde synergistisk med medlemsvirksomhederne og de samarbejdende virksomheder i Andersen Global, samtidig med at vi fortsætter med at udbygge vores kapacitet i Nordeuropa”.
Andersen Global er en international sammenslutning af juridisk adskilte, uafhængige medlemsfirmaer, bestående af skatte- og juraeksperter i hele verden. Andersen Global blev stiftet af den amerikanske medlemsvirksomhed Andersen Tax LLC i 2013 og Andersen Global har nu over 11.000 fagfolk globalt og er repræsenteret på mere end 360 lokaliteter via sine medlemsvirksomheder og samarbejdende virksomheder.
Originalsprogsudgaven af denne bekendtgørelse er den officielle, autoriserede version. Oversættelserne er kun tænkt som en hjælp og bør sammenholdes med kildesprogsteksten, der som den eneste er juridisk bindende.
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20220609005325/da/
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum